# Haplo-PBSC+Cord vs Haplo-PBSC+BM for Hematological Malignancies Undergoing Allo-HSCT

> **NCT05290545** · PHASE3 · COMPLETED · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 314 (actual)

## Conditions studied

- Hematological Malignancies
- Hematopoietic Stem Cell Transplantation

## Interventions

- **OTHER:** PBSCs
- **OTHER:** Cord
- **OTHER:** BMSCs

## Key facts

- **NCT ID:** NCT05290545
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-15
- **Primary completion:** 2023-01-02
- **Final completion:** 2024-03-30
- **Target enrollment:** 314 (ACTUAL)
- **Last updated:** 2024-08-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05290545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05290545, "Haplo-PBSC+Cord vs Haplo-PBSC+BM for Hematological Malignancies Undergoing Allo-HSCT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05290545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*